Delving into the Latest Updates on Norethisterone/Ethinyl estradiol with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Norethisterone/Ethinylestradiol

+ [5]

Target

ER x PR

Mechanism

ERs agonists(Estrogen receptors agonists), PR agonists(Progesterone receptor agonists)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

DysmenorrheaContraception

Inactive Indication

Endometriosis

Originator Organization

Daiichi Seiyaku Co., Ltd.Syntex Corp.

Active Organization

Nobelpharma Co., Ltd.

Kaken Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (16 Jun 1999),

Contraception

Regulation-

Login to view timeline

Structure

Molecular FormulaC40H50O4

InChIKeyNAPPWIFDUAHTRY-XYDRQXHOSA-N

CAS Registry37270-71-6

The purpose of this study is to assess the pharmacokinetic profiles of norethisterone and ethinyl estradiol after single oral administration of NPC-01 in healthy female volunteers.
Pharmacokinetics of norethisterone and ethinyl estradiol will be evaluated on the basis of AUC, Cmax, tmax, t1/2, MRT, kel and AUC∞.

Start Date01 Nov 2010

Sponsor / Collaborator

Nobelpharma Co., Ltd.

100 Clinical Results associated with Norethisterone/Ethinyl estradiol

Login to view more data

100 Translational Medicine associated with Norethisterone/Ethinyl estradiol

Login to view more data

100 Patents (Medical) associated with Norethisterone/Ethinyl estradiol

Login to view more data

3

Literatures (Medical) associated with Norethisterone/Ethinyl estradiol

01 Jun 2018·Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology

[NSD3 suppresses LPS-triggered TNF-α production via promoting the dimethylation of histone H3K36 in macrophages].

Article

Author: Liu, Zhaolong ; Sun, Yanxiang ; Yang, Le ; Cheng, Qijiang

Objective To investigate the role of nuclear receptor-binding SET domain protein 3 (NSD3) in lipopolysaccharide (LPS)-triggered tumor necrosis factor α (TNF-α) production in macrophages and the underlying epigenetic mechanism. Methods The experiment used murine peritoneal macrophages and RAW264.7 cells as cell models. The mRNA and protein level of NSD3 were detected by real-time quantitative PCR and Western blot analysis in mouse peritoneal macrophages stimulated with LPS (100 ng/mL). ELISA was used to detect the production of TNF-α in NSD3-overexpressing RAW264.7 cells or NSD3-silencing peritoneal macrophages. Western blot analysis was performed to test the activation of LPS-triggered NF-κBp65 in NSD3-silencing macrophages. Luciferase assay was used to assess NF-κBp65-mediated transcriptional activation of TNF-α gene. ChIP assay was used to detect the recruitment of H3K36 methylation to TNF-α gene promoter. Results LPS inhibited the expression of NSD3 in the macrophages. Over-expression of NSD3 suppressed LPS-triggered TNF-α production, and silencing NSD3 promoted LPS-triggered TNF-α production. However, NSD3 had no effect on the activation of LPS-triggered NF-κBp65. NSD3 enhanced NF-κBp65-mediated transcriptional activation of TNF-α gene. NSD3 enhanced the dimethylation of H3K36 of TNF-α gene promoter. Conclusion NSD3 can promote the dimethylation of H3K36 of TNF-α gene promoter and suppress TNF-α transcription and production.

01 Dec 2016·Fertility and SterilityQ2 · MEDICINE

Evaluation of an ultra-low-dose oral contraceptive for dysmenorrhea: a placebo-controlled, double-blind, randomized trial

Q2 · MEDICINE

Article

Author: Momoeda, Mikio ; Harada, Tasuku

OBJECTIVETo evaluate the efficacy and safety of an ultra-low-dose oral contraceptive (NPC-01; 0.02 mg ethinyl estradiol and 1 mg norethisterone) in subjects with dysmenorrhea.DESIGNPlacebo-controlled, double-blind, randomized trial.SETTINGClinical trial sites.PATIENT(S)Two hundred fifteen subjects with dysmenorrhea.INTERVENTION(S)Subjects were randomly assigned to receive NPC-01, placebo, or IKH-01 (0.035 mg ethinyl estradiol and 1 mg norethisterone) for four cycles.MAIN OUTCOME MEASURE(S)Total dysmenorrhea score (verbal rating scale) assessing pain on the basis of limited ability to work and need for analgesics.RESULT(S)The reductions of total dysmenorrhea score and visual analog scale score after the treatment were significantly higher in the NPC-01 group than in the placebo group. Furthermore, the efficacy of NPC-01 was comparable to that of IKH-01. The overall incidence of side effects was significantly higher in the NPC-01 group than in the placebo group. All side effects that occurred in the NPC-01 group were previously reported in patients receiving IKH-01. No serious side effects occurred.CONCLUSION(S)The ultra-low-dose contraceptive NPC-01 relieved dysmenorrhea as effectively as IKH-01. Thus, NPC-01 could represent a new option for long-term treatment of dysmenorrhea.CLINICAL TRIAL IDENTIFICATION NUMBERNCT01129102.

01 May 2011·Fertility and SterilityQ2 · MEDICINE

Evaluation of a low-dose oral contraceptive pill for primary dysmenorrhea: a placebo-controlled, double-blind, randomized trial

Q2 · MEDICINE

Article

Author: Yuji Taketani ; Tasuku Harada ; Naoki Terakawa ; Mikio Momoeda ; Hiroshi Hoshiai

OBJECTIVETo evaluate the efficacy and safety of low-dose oral contraceptives (IKH-01; 0.035 mg ethinyl estradiol and 1 mg norethisterone) for patients with primary dysmenorrhea.DESIGNPlacebo-controlled, double-blind, randomized trial.SETTINGClinical trial sites in Japan.PATIENT(S)One hundred fifteen patients with primary dysmenorrhea.INTERVENTION(S)Patients randomly assigned to receive IKH-01 or placebo for four cycles.MAIN OUTCOME MEASURE(S)Total dysmenorrhea score, verbal rating scale defining pain according to limited ability to work and need for analgesics, and visual analog scale (VAS).RESULT(S)Reduction in total dysmenorrhea score and VAS before and after treatment was significantly higher in the IKH-01 group than in the placebo group. Total dysmenorrhea score and VAS in the IKH-01 group significantly decreased from cycles 2 to 5. Overall incidence of adverse events was significantly higher in the IKH-01 group. Incidence decreased over time in the IKH-01 group; it was invariable in the placebo group. No serious adverse events occurred.CONCLUSION(S)IKH-01 could be used as a single agent or in combination with analgesics for treatment of primary dysmenorrhea.

100 Deals associated with Norethisterone/Ethinyl estradiol

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Dysmenorrhea	JP	Nobelpharma Co., Ltd.	16 Apr 2008
Contraception	JP	Kaken Pharmaceutical Co., Ltd.	16 Jun 1999

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Dysmenorrhea	Discovery	-	Nobelpharma Co., Ltd.	01 May 2009
Endometriosis	Discovery	-	Nobelpharma Co., Ltd.	01 May 2009

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01246791 (CTgov)	Phase 3	-	12	NPC-01	pmenpzutfx(veznvkdgkp) = fpevaeyxsv sdgcsczruu (nxkstvoenk, obbvlnncct - zzftxixmcy) View more	-	17 Jun 2014
NCT01129102 (CTgov)	Phase 3	Dysmenorrhea	215	NPC-01 (NPC-01)	xwtffcxyrl(cnczfnbpln) = utoajctewg xmbccbkrnk (fmpcyhcrre, denaolzxru - gzlhhfiqhf) View more	-	17 Jun 2014
				Placebo (Placebo)	xwtffcxyrl(cnczfnbpln) = akpkbwvzaf xmbccbkrnk (fmpcyhcrre, qullbnxyva - fwzbstdhcj) View more
NCT01253824 (CTgov)	Phase 3	-	14	NPC-01 (NPC-01)	semoojecqs(xhwlusyjln) = rdmxjznvyl eqfniousux (zbszdmvptc, iosohbghyb - fssubkgyqm) View more	-	17 Jun 2014
				IKH-01 (IKH-01)	semoojecqs(xhwlusyjln) = zsnmbrwolc eqfniousux (zbszdmvptc, milysirlkc - vnrntyrphk) View more
NCT00902746 (CTgov)	Phase 3	Endometriosis \| Dysmenorrhea	149	NPC-01	icvvecyimt(bvlhtyjytt) = vwfmzrpalx atwscrdgbf (bhuywwphlz, wmjxeybbuz - hnycfrhavl) View more	-	13 Jun 2014
NCT00746096 (CTgov)	Phase 3	Primary dysmenorrhea	115	IKH-01 (IKH-01)	muglwufhzp(bvlkbsroxw) = rvcczsluex kowqbzpgih (ugiwvxjjsq, ogzblwqgqu - uaezcdswyj) View more	-	13 Jun 2014
				Placebo (Placebo)	muglwufhzp(bvlkbsroxw) = gimtsyezfh kowqbzpgih (ugiwvxjjsq, rlkcsvdhpz - bfxonizjsh) View more